Exome Asset Management LLC Takes $2.38 Million Position in Avalo Therapeutics, Inc. $AVTX

Exome Asset Management LLC bought a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 159,341 shares of the company’s stock, valued at approximately $2,379,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AVTX. Geode Capital Management LLC boosted its position in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after purchasing an additional 2,648 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares in the last quarter. Bank of America Corp DE lifted its stake in Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after purchasing an additional 400,898 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics during the second quarter valued at approximately $56,000. Finally, Vanguard Group Inc. boosted its holdings in Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Avalo Therapeutics

In other news, CFO Christopher Ryan Sullivan sold 8,458 shares of the company’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the transaction, the chief financial officer owned 8,880 shares in the company, valued at $116,239.20. This represents a 48.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,428 shares of company stock valued at $1,762,722 in the last 90 days. 4.46% of the stock is currently owned by corporate insiders.

Avalo Therapeutics Trading Up 5.7%

Shares of AVTX stock opened at $19.50 on Tuesday. Avalo Therapeutics, Inc. has a 1-year low of $6.21 and a 1-year high of $24.27. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.57 and a beta of 0.78. The stock’s fifty day simple moving average is $16.81 and its 200-day simple moving average is $16.14.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, sell-side analysts predict that Avalo Therapeutics, Inc. will post -2.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AVTX shares. Wedbush reduced their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Friday. Mizuho increased their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, Leerink Partners began coverage on Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.80.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.